The Magazine for Sleep Professionals
Sunday, April 5, 2026
The Alliance of Sleep Apnea Partners (ASAP) announces the return of Sleep Apnea Education Week, April 18-26, 2025. This annual awareness campaign aims to educate the public about sleep apnea, a serious sleep disorder that affects millions of Americans and has significant implications for both individual health and public health […]
At Wake Up Narcolepsy (WUN), our hybrid approach to programs and events has transformed and expanded how we connect with people affected by narcolepsy. For those living with rare or misunderstood disorders like narcolepsy, connecting with others is often life-changing. It provides a sense of belonging that eases some of […]
Just a few days ago, an estimated 200 million viewers watched as the Philadelphia Eagles and the Kansas City Chiefs faced off in New Orleans during the biggest game of the National Football League’s season. What many sports fans—and even players—don’t realize is that a significant number of these pro […]
The thought of histamines might conjure up images of itchy hives or the tickling sensation just before a sneeze, but scientists have come to realize there is much more to histamines than their connection to allergies. Recent research reveals that histamines play a vital role in wakefulness. Produced by brain […]
Panthera Dental, a global leader in CAD/CAM implant solutions and dental sleep medical devices, proudly announces the launch of its best-in-class BioMatch System, set to streamline the field of oral appliance therapy (OAT). The BioMatch System is designed to make ordering of a patient-matched appliance an effortless process, ease dental […]
Since its inception in 2008, Wake Up Narcolepsy (WUN) has donated over $1.39 million to narcolepsy research. We are a nonprofit organization committed to advancing narcolepsy awareness, education, and research. A large part of our mission involves raising and allocating funding to develop improved treatments and ultimately, find a cure. […]
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with […]
Similar to its prevalence in the adult population, obstructive sleep apnea (OSA) in children is one of the most common manifestations of sleep-related breathing disorders. The prevalence of OSA in children has significantly increased in the last 20 years, particularly among the younger population, possibly linked to the rise in […]
A new clinical practice guideline developed by the American Academy of Sleep Medicine provides updated recommendations for the treatment of restless legs syndrome. The guideline reflects the latest scientific evidence and recommends significant changes in the standard treatment of RLS in adults. Available online as an accepted paper in the […]
LivaNova PLC, a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment […]
